NEW YORK (TheStreet) -- Shares of Stryker Corp. (SYK - Get Report) are surging, up 3.21% to $82.94, even though the medical technology company denied a Financial Times report that said it plans to bid for orthopedics firm Smith & Nephew (SNN - Get Report).
Smith & Nephew shares have jumped 3.88% to $83.46.
The U.K. Takeover Panel asked for the statement, according to Stryker.
- SYK's revenue growth has slightly outpaced the industry average of 3.3%. Since the same quarter one year prior, revenues slightly increased by 5.3%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
- The current debt-to-equity ratio, 0.34, is low and is below the industry average, implying that there has been successful management of debt levels. To add to this, SYK has a quick ratio of 1.54, which demonstrates the ability of the company to cover short-term liquidity needs.
- The gross profit margin for STRYKER CORP is rather high; currently it is at 68.89%. Regardless of SYK's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 3.03% trails the industry average.
- STRYKER CORP has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has suffered a declining pattern of earnings per share over the past two years. However, we anticipate this trend to reverse over the coming year. During the past fiscal year, STRYKER CORP reported lower earnings of $2.63 versus $3.39 in the prior year. This year, the market expects an improvement in earnings ($4.82 versus $2.63).
- Compared to where it was a year ago today, the stock is now trading at a higher level, regardless of the company's weak earnings results. The stock's price rise over the last year has driven it to a level which is somewhat expensive compared to the rest of its industry. We feel, however, that other strengths this company displays justify these higher price levels.
- You can view the full analysis from the report here: SYK Ratings Report